Dupilumab — the human monoclonal antibody targeting the IL-4Rα receptor blocking both IL-4 and IL-13 signaling that has revolutionized moderate-to-severe atopic dermatitis treatment — represents the most commercially successful dermatology product ever launched, with the Atopic Dermatitis Market reflecting the transformation that targeted biologic therapy has created in the AD...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Portuguese
Italiano
Romaian
china